Jennifer Altamira
Acute Care · Mission Viejo, CANPI 1205815248
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.9% of the total across 208 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,761, more than ten times the $146 reported in 2021. Among acute care clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $28.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$819
- Amgen$590
- AOP Health US, LLC$488
- Boehringer Ingelheim$376
- Edwards Lifesciences$343
- Merck$342
- plus $3K from 26 others
What the payments were for
- Travel & lodging$3035%
- Food & beverage$5,59695%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 40 | $819 |
| Amgen | 30 | $590 |
| AOP Health US, LLC | 1 | $488 |
| Boehringer Ingelheim | 16 | $376 |
| Edwards Lifesciences | 2 | $343 |
| Merck | 8 | $342 |
| Bayer | 9 | $334 |
| Bard Peripheral Vascular, Inc. | 2 | $303 |
| Alnylam Pharmaceuticals Inc. | 10 | $256 |
| AstraZeneca | 13 | $217 |
| Johnson & Johnson | 10 | $210 |
| E.r. Squibb & Sons, L.L.C. | 9 | $176 |
| Abbott | 3 | $171 |
| Kiniksa Pharmaceuticals, Ltd. | 7 | $169 |
| Regeneron Healthcare Solutions, Inc. | 5 | $149 |
| Pfizer | 6 | $143 |
| Novo Nordisk | 5 | $111 |
| Lantheus Medical Imaging, Inc. | 5 | $95 |
| Abiomed | 4 | $84 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $75 |
| Sanofi-aventis U.S. LLC | 3 | $67 |
| Tactile Systems Technology Inc | 1 | $51 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $51 |
| Actelion Pharmaceuticals US, Inc. | 2 | $50 |
| Bridgebio Pharma, Inc. | 2 | $39 |
| Kestra Medical Technology Services, Inc. | 2 | $38 |
| Scpharmaceuticals Inc. | 1 | $37 |
| Boston Scientific | 1 | $35 |
| Cvrx, Inc. | 1 | $29 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Amryt Pharma Holdings Ltd | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,899 in reported general payments places this provider in the 90th percentile of 1,153 acute care providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 42 | $47,326 |
| Repatha SureclickEvolocumab | 40 | $38,533 |
| EliquisApixaban | 22 | $33,918 |
| XareltoRivaroxaban | 23 | $24,955 |
| Repatha SyringeEvolocumab | 12 | $9,481 |
| LivaloPitavastatin Calcium | 13 | $6,841 |
| Rosuvastatin Calcium | 138 | $2,068 |
| Atorvastatin Calcium | 186 | $1,709 |
| Metoprolol Succinate | 91 | $1,426 |
| Ezetimibe | 68 | $1,296 |
| Losartan Potassium | 153 | $1,229 |
| ClopidogrelClopidogrel Bisulfate | 90 | $1,191 |
| Olmesartan Medoxomil | 49 | $1,094 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 18 | $983 |
| Nitroglycerin | 43 | $958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $819 | $47,32642 claims |
| PfizerEliquis | $143 | $33,91822 claims |
| Johnson & JohnsonXarelto | $210 | $24,95523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,153 acute care providers in California.
Other acute care in Mission Viejo
- Chelsea ZimmermanMission Viejo$22K
- Diana TaiMission Viejo$22K
- Leslie PetersenCamarillo$370K
- Joyce KhremianSan Dimas$73K
- Eleanor VierraSacramento$64K
- Frances DyLos Angeles$57K
- Savannah HarrisVentura$56K
- Kori Ann JohnstonLos Angeles$42K
- Caroline KwongOrange$42K
- Gregory KnutzenColton$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.